Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict

(Reuters) - A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck& Co Inc.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news